Document is current
Any future updates will be listed below
-
Authors
López-Erauskin, Jone
Bravo-Hernandez, Mariana
Presa, Maximiliano https://orcid.org/0000-0002-0160-6528
Baughn, Michael W. https://orcid.org/0000-0001-8525-8024
Melamed, Ze’ev
Beccari, Melinda S. https://orcid.org/0000-0003-1019-6388
Agra de Almeida Quadros, Ana Rita https://orcid.org/0000-0002-6909-2420
Arnold-Garcia, Olatz https://orcid.org/0000-0003-3312-4790
Zuberi, Aamir
Ling, Karen https://orcid.org/0000-0002-5895-6684
Platoshyn, Oleksandr
Niño-Jara, Elkin
Ndayambaje, I. Sandra https://orcid.org/0000-0002-8099-2307
McAlonis-Downes, Melissa
Cabrera, Larissa
Artates, Jonathan W.
Ryan, Jennifer
Hermann, Anita
Ravits, John
Bennett, C. Frank
Jafar-Nejad, Paymaan
Rigo, Frank
Marsala, Martin
Lutz, Cathleen M. https://orcid.org/0000-0003-2502-1900
Cleveland, Don W. https://orcid.org/0000-0002-1934-3682
Lagier-Tourenne, Clotilde https://orcid.org/0000-0002-3058-8322
- License Information
-
More Information
Article History
Received: 21 August 2022
Accepted: 16 October 2023
First Online: 23 November 2023
Competing interests
: C.F.B., M.B.-H., K.L., P.J.-N. and F.R. are employees of Ionis Pharmaceuticals. D.W.C. is a consultant for Ionis Pharmaceuticals. Z.M. and D.W.C. have a relevant patent. C.L.-T. serves on the scientific advisory board of SOLA Biosciences, Libra Therapeutics, Arbor Biotechnologies and Dewpoint Therapeutics, and has received consultant fees from Mitsubishi Tanabe Pharma Holdings America and Applied Genetic Technologies Corporation. All other authors declare no competing interests.
